Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2013
|
| gptkbp:ATCCode |
gptkb:J05AX12
|
| gptkbp:CASNumber |
1051375-16-6
|
| gptkbp:chemicalFormula |
C20H19F2N3O5
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:eliminationHalfLife |
14 hours
|
| gptkbp:genericName |
gptkb:dolutegravir
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tivicay
|
| gptkbp:isApprovedDrug |
true
|
| gptkbp:KEGGID |
D09952
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:ViiV_Healthcare
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B
B1 |
| gptkbp:proteinBinding |
>98.9%
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2176937
gptkb:DB08930 54726191 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache insomnia |
| gptkbp:UNII |
GMP79G6X04
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:dolutegravir
|
| gptkbp:bfsLayer |
6
|